Skip to content

Sandra D Comer

4 papers in the library · 63 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of psychopharmacology (Oxford, England) 2026 Jack E Henningfield, Sandra D Comer, Matthew L Banks et al. 5 citations

Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...

Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.

The Journal of pharmacology and experimental therapeutics October 18, 2024 Rachel Luba, Gabriela Madera, Rebecca Schusterman et al. 2 citations

Endocannabinoids, which are present throughout the central nervous system (CNS), can activate cannabinoid receptors 1 and 2 (CB1 and CB2). CB1 and CB2 agonists exhibit broad anti-inflammatory properties, suggesting their potential to treat inflammatory diseases. However, careful evaluation of abuse potential is necessary. This study evaluated the abuse potential of lenabasum, a selective CB2...

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

JAMA Psychiatry 2023 Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al. 22 citations

Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Neuropharmacology August 17, 2022 Jack E Henningfield, Marion A Coe, Roland R. Griffiths et al. 34 citations

New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...